Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.5.1.52 (
PNGase F
)
1,527
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Erythropoietin (EPO) and its cell surface receptor (
EPOR
) are essential for erythropoiesis; can modulate non-erythroid target tissues; and have been reported to affect the progression of certain cancers. Basic studies of
EPOR
expression and trafficking, however, have been hindered by low-level
EPOR
occurrence, and the limited specificity of anti-
EPOR
antibodies. Consequently, these aspects of
EPOR
biology are not well defined, nor are actions of polycythemia- associated mutated
EPOR
alleles. Using novel rabbit monoclonal antibodies to intracellular, PY- activated and extracellular
EPOR
domains, the following properties of the endogenous hEPOR in erythroid progenitors first are unambiguously defined. 1) High- Mr
EPOR
forms become obviously expressed only when EPO is limited. 2)
EPOR
-68K plus -70K species sequentially accumulate, and
EPOR
-70K comprises an apparent cell surface
EPOR
population. 3) Brefeldin A,
N-glycanase
and associated analyses point to
EPOR
-68K as a core-glycosylated intracellular
EPOR
pool (of modest size). 4) In contrast to recent reports,
EPOR
inward trafficking is shown (in UT7epo cells, and primary proerythroblasts) to be sharply ligand-dependent. Beyond this, when C-terminal truncated hEPOR-T mutant alleles as harbored by polycythemia patients are co-expressed with the wild-type
EPOR
in EPO-dependent erythroid progenitors, several specific events become altered. First,
EPOR
-T alleles are persistently activated upon EPO- challenge, yet are also subject to apparent turn-over (to low-Mr
EPOR
products). Furthermore, during exponential cell growth
EPOR
-T species become both over-represented, and hyper-activated. Interestingly,
EPOR
-T expression also results in an EPO dose-dependent loss of endogenous wild-type
EPOR
's (and, therefore, a squelching of
EPOR
C-terminal- mediated negative feedback effects). New knowledge concerning regulated
EPOR
expression and trafficking therefore is provided, together with new insight into mechanisms via which mutated
EPOR
-T polycythemia alleles dysregulate the erythron. Notably, specific new tools also are characterized for studies of
EPOR
expression, activation, action and metabolism.
...
PMID:Dynamic ligand modulation of EPO receptor pools, and dysregulation by polycythemia-associated EPOR alleles. 2225 4